當前位置:首頁 > English > Health News > Two-StepEbolaVaccineWorksinEarlyTrial

Two-StepEbolaVaccineWorksinEarlyTrial

來源:WebMDMedicalNews 作者: 2016-4-20

摘要: By Dennis Thompson HealthDay Reporter TUESDAY, April 19, 2016 (HealthDay News) -- A new two-step Ebola vaccine strategy has shown some promise in early clinical trials。 The trials involved two candidate Ebola vaccines that were given to volunteers in separate sho......


By Dennis Thompson

HealthDay Reporter

TUESDAY, April 19, 2016 (HealthDay News) -- A new two-step Ebola vaccine strategy has shown some promise in early clinical trials.

The trials involved two candidate Ebola vaccines that were given to volunteers in separate shots, the researchers said. One vaccine was provided first as a "primer" shot, and the second was given as a "booster."

The winning combo was a "primer" shot of a genetically engineered cold virus (AD-26), followed by a "booster" shot of a similarly altered smallpox virus (MVA), according to the report.

In both cases, the viruses had been altered to include genetic material from Ebola, so any immune response to the vaccine could theoretically promote immunity to Ebola, the study authors explained.

An immune response was observed after primary immunization with the AD-26 vaccine, and boosting with the MVA resulted in sustained elevation of specific immunity to Ebola, the researchers found.

Further, neither vaccine caused any serious adverse events in the 87 people, aged 18 to 50, who volunteered for the phase 1 clinical trial.

The findings were published April 19 in the Journal of the American Medical Association.

The recent West African outbreak of Ebola, the largest in history, killed more than 11,000 people and infected more than 28,000, according to the U.S. Centers for Disease Control and Prevention.

Ebola expert Dr. Lee Norman, chief medical officer for the University of Kansas Hospital, said it's good that researchers are investigating different ways of delivering vaccines for the deadly virus.

"The delivery method, if it is successful, is really an important building block for a successful vaccine," Norman said. "We have to remind ourselves that phase 1 trials are typically more about safety than about effectiveness. It isn't typically the goal of a phase 1 trial to emphasize effectiveness."

Dr. Amesh Adalja, a senior associate at the UPMC Center for Health Security in Baltimore, agreed.

"Since the West African Ebola outbreak, many different vaccine approaches have flourished, and with several promising candidate vaccines the manner in which future Ebola outbreaks will be managed will be dramatically improved," Adalja said.


醫學百科App—醫學基礎知識學習工具


頁:
返回頂部】【打印本文】【放入收藏夾】【收藏到新浪】【發布評論


察看關于《Two-StepEbolaVaccineWorksinEarlyTrial》的討論


關閉

網站地圖 | RSS訂閱 | 圖文 | 版權說明 | 友情鏈接
Copyright © 2008 39kf.com All rights reserved. 醫源世界 版權所有
醫源世界所刊載之內容一般僅用于教育目的。您從醫源世界獲取的信息不得直接用于診斷、治療疾病或應對您的健康問題。如果您懷疑自己有健康問題,請直接咨詢您的保健醫生。醫源世界、作者、編輯都將不負任何責任和義務。
本站內容來源于網絡,轉載僅為傳播信息促進醫藥行業發展,如果我們的行為侵犯了您的權益,請及時與我們聯系我們將在收到通知后妥善處理該部分內容